Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1/2 1Phase 1 1

Status

Recruiting 2Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Nasopharyngeal Carcinoma 20Carcinoma, Non-Small-Cell Lung 18Esophageal Squamous Cell Carcinoma 15Breast Neoplasms 14Triple Negative Breast Neoplasms 13Squamous Cell Carcinoma of Head and Neck 11Carcinoma, Hepatocellular 11Stomach Neoplasms 8Small Cell Lung Carcinoma 8Uterine Cervical Neoplasms 6Recurrence 6Head and Neck Neoplasms 6Colorectal Neoplasms 6Carcinoma, Transitional Cell 5Carcinoma, Renal Cell 5Urinary Bladder Neoplasms 4Sarcoma 4Rectal Neoplasms 4Neoplasm Metastasis 4Melanoma 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Locally Advanced Rectal Cancer 3Liver Neoplasms 3Turcot syndrome 2Pathologic Complete Response 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Nasopharyngeal Neoplasms 2

Interventions

pembrolizumab 31Gemcitabine 26Nivolumab 20atezolizumab 16Cisplatin 15avelumab 14Carboplatin 12Docetaxel 10enfortumab vedotin 8Magnetic Resonance Spectroscopy 8durvalumab 7Specimen Handling 7Paclitaxel 7Ipilimumab 6toripalimab 5pemigatinib 5cabozantinib 5vinflunine 4sacituzumab govitecan 4Taxes 4Pemetrexed 4tislelizumab 3cabazitaxel 3Standard of Care 3Mitomycin 3Injections 3Everolimus 3Albumin-Bound Paclitaxel 3sapanisertib 2olaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Transitional Cell × toripalimab × Clear all
NCT04553939 2026-01-02

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

Henan Cancer Hospital

Phase 2 Completed
50 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07314723 2026-01-02

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 2 Recruiting
90 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT07189793 2025-09-24

OHAI-NMIBC-01

First Affiliated Hospital of Wenzhou Medical University

Phase 2 Not yet recruiting
106 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT06823427 2025-03-21

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 2 Recruiting
60 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT04211012 2020-11-13

A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma

Peking University Cancer Hospital & Institute

Phase 2 Unknown
30 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡